FDA wants another look at data for failed drugs

Share this article:
©Kantar Media ©JARScan ad images database
©Kantar Media ©JARScan ad images database

FDA's drugs center wants to revisit a proposal once entertained by PhRMA to allow the agency access to all data from failed drug development programs to research whether different approaches could have saved the products.

The idea was explored before, but an agreement was never reached. CDER deputy director for clinical science Bob Temple is pitching it again based on statements that the industry is more willing to share internal data.

Phase 3 failures continue at an alarming rate, Temple acknowledged during a joint FDA/Drug Information Association workshop on drug development in Bethesda, MD. These “destroy optimism,” he said, adding that at least 10 years ago there were discussions with PhRMA “about a completely open review of drugs that failed in Phase 3.”

Temple's pitch followed his presentation on how better dose-response data could have saved products removed from the market after approval. For example, Lotronex, for IBS associated with diarrhea, was pulled because of severe side effects at its original dose, but is back on the market at a reduced dose.
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Journal Ad Review: Reality Bites

Journal Ad Review: Reality Bites

Print's numbers may be taking some small steps in the right direction, but data is what the industry really wants to sink its teeth into. Larry Dobrow reports on what ...

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...